Clinical Outcomes of Postoperative Three-weekly Cisplatin for High-risk Head and Neck Squamous Cell Carcinoma

Background/Aim: Microscopic positive margins and extranodal extension are established pathological risk factors for recurrence after curative surgery for head and neck squamous cell carcinoma. Postoperative radiotherapy with concurrent cisplatin is the standard treatment for such patients. We evaluated the outcomes of postoperative radiotherapy administered concurrently with three-weekly cisplatin and explored factors associated with disease-free survival. Patients and Methods: We retrospectively analyzed patients with head and neck squamous cell carcinoma who started postoperative radiotherapy with concurrent cisplatin between April 2015 and December 2023. Eligible patients had microscopic positive margins or extranodal extension and received postoperative radiotherapy concurrently with three-weekly cisplatin. The primary endpoint was disease-free survival. Secondary endpoints included overall survival, recurrence patterns, and factors associated with disease-free survival. Results: We included 83 patients (median age, 62 years; 68 men). The 5-year disease-free and overall survival rates were 55.5% and 67.9%, respectively, and neither median was reached. Distant metastasis developed in 23 patients (27.7%), with 1-year and 5-year cumulative rates of 21.3% and 28.8%, respectively. In univariate analysis, radiotherapy dose <60 Gy, perineural invasion, and venous invasion were associated with poorer disease-free survival. Disease-free survival did not differ according to cumulative cisplatin dose (≥200 vs. <200 mg/m2). Conclusion: Postoperative radiotherapy administered concurrently with three-weekly cisplatin was associated with 5-year disease-free and overall survival rates of 55.5% and 67.9%, respectively, in routine clinical practice. Perineural and venous invasion may provide additional prognostic information beyond established high-risk pathological features. The frequency of distant metastasis suggests the need for strategies that improve both locoregional and systemic control.

Authors

Institutions

Publication Details

Journal
Anticancer Research
Published
2026-10-27
DOI
https://doi.org/10.21873/anticanres.18457
Primary Topic
Head and Neck Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical Outcomes of Postoperative Three-weekly Cisplatin for High-risk Head and Neck Squamous Cell Carcinoma

Kiyoaki Tsukahara, Kenji Hanyu, Isaku Okamoto, Kosuke Hihara et al.
Anticancer Research
Head and Neck Cancer Studies
article

Clinical Outcomes of Postoperative Three-weekly Cisplatin for High-risk Head and Neck Squamous Cell Carcinoma

Kiyoaki Tsukahara, Kenji Hanyu, Isaku Okamoto, Kosuke Hihara, Tomohiro Itonaga, Yusuke Aihara, Yuri Ueda, HIDEKI TANAKA, ATSUHIKO ZAMA
article en

Abstract

Background/Aim: Microscopic positive margins and extranodal extension are established pathological risk factors for recurrence after curative surgery for head and neck squamous cell carcinoma. Postoperative radiotherapy with concurrent cisplatin is the standard treatment for such patients. We evaluated the outcomes of postoperative radiotherapy administered concurrently with three-weekly cisplatin and explored factors associated with disease-free survival. Patients and Methods: We retrospectively analyzed patients with head and neck squamous cell carcinoma who started postoperative radiotherapy with concurrent cisplatin between April 2015 and December 2023. Eligible patients had microscopic positive margins or extranodal extension and received postoperative radiotherapy concurrently with three-weekly cisplatin. The primary endpoint was disease-free survival. Secondary endpoints included overall survival, recurrence patterns, and factors associated with disease-free survival. Results: We included 83 patients (median age, 62 years; 68 men). The 5-year disease-free and overall survival rates were 55.5% and 67.9%, respectively, and neither median was reached. Distant metastasis developed in 23 patients (27.7%), with 1-year and 5-year cumulative rates of 21.3% and 28.8%, respectively. In univariate analysis, radiotherapy dose <60 Gy, perineural invasion, and venous invasion were associated with poorer disease-free survival. Disease-free survival did not differ according to cumulative cisplatin dose (≥200 vs. <200 mg/m2). Conclusion: Postoperative radiotherapy administered concurrently with three-weekly cisplatin was associated with 5-year disease-free and overall survival rates of 55.5% and 67.9%, respectively, in routine clinical practice. Perineural and venous invasion may provide additional prognostic information beyond established high-risk pathological features. The frequency of distant metastasis suggests the need for strategies that improve both locoregional and systemic control.

Anticancer ResearchVol. 46(11)
Tokyo Medical University (JP)
Good health and well-being
Openalex Percentile: Top 10%
Head and Neck Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon